American Society of Hematology

Figure 1

$Figure 1. Antibodies to human fXII. (A) Schematic diagrams comparing the domain structures of fXII and its homolog HGFA. Arrowed numbers indicate the locations of amino acid pairs that were used to create splice sites for introduction of HGFA domains into fXII to create fXII/HGFA chimeras. (B) Western blots of nonreduced human (H) and baboon (B) plasma size-fractionated by sodium dodecyl sulfate-PAGE. The primary anti-factor XII antibodies used for detection are indicated at the top of each panel. (C) Western blots of wild-type human fXII (FXII) and human fXII with the first or second epidermal growth factor (EGF1 or EGF2), fibronectin type 1 (Fib-1), kringle (KNG), or proline-rich (ProR) domains replaced with the corresponding HGFA domain. Primary antibodies are indicated to the left of each blot. Poly, Polyclonal goat IgG against human fXII.$

Antibodies to human fXII. (A) Schematic diagrams comparing the domain structures of fXII and its homolog HGFA. Arrowed numbers indicate the locations of amino acid pairs that were used to create splice sites for introduction of HGFA domains into fXII to create fXII/HGFA chimeras. (B) Western blots of nonreduced human (H) and baboon (B) plasma size-fractionated by sodium dodecyl sulfate-PAGE. The primary anti-factor XII antibodies used for detection are indicated at the top of each panel. (C) Western blots of wild-type human fXII (FXII) and human fXII with the first or second epidermal growth factor (EGF1 or EGF2), fibronectin type 1 (Fib-1), kringle (KNG), or proline-rich (ProR) domains replaced with the corresponding HGFA domain. Primary antibodies are indicated to the left of each blot. Poly, Polyclonal goat IgG against human fXII.

This Feature Is Available To Subscribers Only